证券之星消息，9月4日中药板块较上一交易日下跌0.82%，ST香雪领跌。当日上证指数报收于3765.88， 下跌1.25%。深证成指报收于12118.7，下跌2.83%。中药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 002082 | 万邦德 | 9.98 | 3.42% | 48.71万 | 4.82亿 | | 833266 | 生物谷 | 11.20 | 2.38% | 3.93万 | 4412.26万 | | 600080 | 金花股份 | 7.39 | 2.07% | 6.34万 | 4679.06万 | | 000590 | 启迪药业 | 11.91 | 1.71% | 7.76万 | 9193.90万 | | 603139 | 康惠制药 | 23.45 | 1.38% | 2.16万 | 5072.80万 | | 301111 | 粤万年青 | 16.44 | 1.36% | 2.85万 | 4702.56万 | | 300519 | 新光药业 | 16.1 ...

Market Overview - The Chinese medicine sector rose by 0.75% on September 1, with Zhendong Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3875.53, up 0.46%, while the Shenzhen Component Index closed at 12828.95, up 1.05% [1] Top Gainers in Chinese Medicine Sector - Zhendong Pharmaceutical (300158) closed at 9.21, up 6.11% with a trading volume of 1.2136 million shares and a turnover of 1.101 billion yuan [1] - Qidi Pharmaceutical (000590) closed at 12.33, up 4.14% with a trading volume of 140,800 shares and a turnover of 174 million yuan [1] - Kangmei Pharmaceutical (600518) closed at 2.12, up 3.92% with a trading volume of 5.5195 million shares and a turnover of 1.165 billion yuan [1] Top Losers in Chinese Medicine Sector - Tianmu Pharmaceutical (600671) closed at 19.44, down 1.87% with a trading volume of 86,000 shares and a turnover of 170 million yuan [2] - Jilin Aodong (000623) closed at 20.13, down 1.66% with a trading volume of 284,000 shares and a turnover of 573 million yuan [2] - *ST Changyao (300391) closed at 4.19, down 1.64% with a trading volume of 86,000 shares and a turnover of 36.1 million yuan [2] Capital Flow Analysis - The Chinese medicine sector experienced a net outflow of 29.7085 million yuan from institutional investors, while retail investors saw a net inflow of 253 million yuan [2][3] - Notable net inflows from retail investors were observed in Yunnan Baiyao (000538) with 436.788 million yuan and in Zhongsheng Pharmaceutical (002317) with 82.0845 million yuan [3] Individual Stock Capital Flow - Yunnan Baiyao (000538) had a net inflow of 188 million yuan from institutional investors, but a net outflow of 144 million yuan from speculative funds [3] - Zhongsheng Pharmaceutical (002317) saw a net inflow of 54.7945 million yuan from institutional investors, while retail investors experienced a net outflow of 82.0845 million yuan [3] - Dong'e Ejiao (000423) had a net inflow of 53.6307 million yuan from institutional investors, with a net outflow of 40.1030 million yuan from speculative funds [3]

据证券之星公开数据整理，近期康惠制药（603139）发布2025年中报。截至本报告期末，公司营业总收 入2.48亿元，同比下降6.83%，归母净利润-4020.36万元，同比下降362.01%。按单季度数据看，第二季 度营业总收入1.26亿元，同比下降8.76%，第二季度归母净利润-2296.43万元，同比下降134.61%。本报 告期康惠制药短期债务压力上升，流动比率达0.96。 本次财报公布的各项数据指标表现不尽如人意。其中，毛利率26.44%，同比减19.17%，净利 率-23.17%，同比减259.76%，销售费用、管理费用、财务费用总计1.11亿元，三费占营收比44.93%，同 比增19.54%，每股净资产8.18元，同比减13.12%，每股经营性现金流-0.17元，同比减19.36%，每股收 益-0.4元，同比减344.44% | 项目 | 2024年中报 | 2025年中报 | 同比增幅 | | --- | --- | --- | --- | | 营业总收入(元) | 2.66亿 | 2.48 Z | -6.83% | | 归母净利润(元) | -870.2万 | -4020.36万 | -36 ...

Core Viewpoint - The company is holding a shareholders' meeting to discuss various governance changes, including the abolition of the supervisory board and amendments to the company's articles of association [5][6][7]. Meeting Procedures - All attendees must register 30 minutes prior to the meeting and present valid identification to participate in voting and discussions [1][2]. - Shareholders have the right to speak, inquire, and vote during the meeting, but must register to speak 15 minutes before the meeting starts [2][3]. - The meeting will utilize both on-site and online voting methods, with each share entitled to one vote [2][3]. Agenda Items - Proposal to abolish the supervisory board and amend the articles of association, transferring the supervisory functions to the audit committee of the board [5]. - Amendments to the rules governing shareholder meetings to enhance corporate governance [6]. - Amendments to the rules governing board meetings to improve operational standards [7]. - Proposal to revise the independent director system to align with regulatory requirements [8]. - Proposal to amend the external investment management system to ensure compliance with legal standards [9]. - Proposal to revise the external guarantee management system to enhance risk management [9]. - Proposal to amend the related party transaction management system to ensure transparency [10]. - Proposal to revise the accountant selection system to ensure proper financial oversight [11]. - Election of the sixth board of directors, including both non-independent and independent directors, due to the expiration of the current board's term [12][13]. Meeting Logistics - The meeting is scheduled for September 4, 2025, at 2:30 PM, with specific time slots for online voting [3][4]. - The venue for the meeting is located at the company's headquarters in Xi'an [4]. Legal Oversight - The meeting will be witnessed by a law firm to ensure compliance with legal standards and provide a legal opinion on the proceedings [3].

股票简称：康惠制药 股票代码：603139 2025 年第二次临时股东大会 会议资料 陕西康惠制药股份有限公司 2025 年 9 月 2025 年第二次临时股东大会会议资料 目 录 | 陕西康惠制药股份有限公司 | 2025 年第二次临时股东大会会议须知 | - | 1 - | | --- | --- | --- | --- | | 陕西康惠制药股份有限公司 | 2025 年第二次临时股东大会会议议程 | - | 3 - | | 陕西康惠制药股份有限公司 | 2025 年第二次临时股东大会会议议案 | - | 5 - | | 议案一 | 关于取消公司监事会并修订《公司章程》的议案 | - | 5 - | | 议案二 | 关于修订《股东会议事规则》的议案 | - | 6 - | | 议案三 | 关于修订《董事会议事规则》的议案 | - | 7 - | | 议案四 | 关于修订《独立董事制度》的议案 | - | 8 - | | 议案五 | 关于修订《对外投资管理制度》的议案 | - | 9 - | | 议案六 | 关于修订《对外担保管理制度》的议案 | - | 10 - | | 议案七 | 关于修订《关联交易管理 ...

Core Viewpoint - The company, Kanghui Pharmaceutical, has released its semi-annual report for 2025, emphasizing the importance of reviewing the full report for a comprehensive understanding of its operational results, financial status, and future development plans [1]. Company Overview - Kanghui Pharmaceutical is identified by the stock code 603139 and is based in Shaanxi, China [2]. - The report indicates that all board members attended the board meeting, and the report has not been audited [2]. Financial Data - The company has provided key financial data in the report, although specific figures are not disclosed in the excerpts [2]. - The report includes information on the top 10 shareholders and their holdings, but details are not provided in the excerpts [2]. Important Matters - The company is required to disclose significant changes in its operational situation during the reporting period and any events that may have a substantial impact on its operations [3].

格隆汇8月26日｜康惠制药（维权）披露的半年报显示，公司上半年实现营业收入2.48亿元，同比下降 6.83%；归属于上市公司股东的净利润亏损4020.36万元，上年同期亏损870.2万元。 ...

陕西康惠制药股份有限公司 2025 年半年度报告 公司代码：603139 公司简称：康惠制药 陕西康惠制药股份有限公司 二 O 二五年八月 陕西康惠制药股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人王延岭 、主管会计工作负责人邹滨泽 及会计机构负责人（会计主管人员） 白丽丽声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中如有涉及未来计划、发展战略等前瞻性陈述，不构成公司对投资者实质承诺，敬请投资 者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内， ...

Core Viewpoint - The announcement presents the key operating data for the first half of 2025 for Shaanxi Kanghui Pharmaceutical Co., Ltd, highlighting a decline in revenue and profitability across various segments compared to the previous year [1][2]. Summary by Category Main Business Revenue by Industry - The total operating revenue for the company was 241.27 million yuan, a decrease of 7.24% compared to the previous year. The operating cost was 178.51 million yuan, which increased by 1.79%, resulting in a gross margin of 26.01%, down by 6.57% [2][3]. Main Business Revenue by Product Use - The revenue breakdown by product categories shows: - Gynecology: Revenue of 16.97 million yuan, down 18.36% year-on-year, with a gross margin of 52.99% - Respiratory and Cold: Revenue of 19.59 million yuan, down 16.12%, with a gross margin of 32.36% - Dermatology: Revenue of 32.26 million yuan, down 14.07%, with a gross margin of 67.96% - Orthopedics: Revenue of 15.47 million yuan, up 11.01%, with a gross margin of 40.99% - Others: Revenue of 32.62 million yuan, up 84.78%, with a gross margin of 48.72% - Traditional Chinese Medicine: Revenue of 14.26 million yuan, down 44.26%, with a negative gross margin of -2.96% - Pharmaceutical Intermediates: Revenue of 18.30 million yuan, up 906.55%, with a negative gross margin of -60.68% - Pharmaceutical Distribution: Revenue of 91.80 million yuan, down 23.14%, with a gross margin of 16.12% [2][3]. Main Business Revenue by Region - The revenue by region indicates: - Northeast: 9.71 million yuan, down 28.96% - North China: 24.29 million yuan, down 0.25% - East China: 45.14 million yuan, up 4.78% - South China: 16.91 million yuan, down 17.46% - Central China: 22.46 million yuan, down 1.64% - Northwest: 101.06 million yuan, up 10.12% - Southwest: 21.71 million yuan, down 50.58% [3].

公司代码：603139 公司简称：康惠制药 陕西康惠制药股份有限公司 2025 年半年度报告 二 O 二五年八月 陕西康惠制药股份有限公司 2025 年半年度报告 1 / 184 陕西康惠制药股份有限公司 2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人王延岭 、主管会计工作负责人邹滨泽 及会计机构负责人（会计主管人员） 白丽丽声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 十一、 其他 √适用 □不适用 本报告中如有涉及未来计划、发展战略等前瞻性陈述，不构成公司对投资者实质承诺，敬请投资 者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实 ...